BioCentury
ARTICLE | Financial News

Accelerator leads Rodeo's series A round

July 25, 2017 1:28 PM UTC

Newly launched Rodeo Therapeutics Corp. (Seattle, Wash.) raised $5.9 million in a series A round led by Accelerator Corp. (Seattle, Wash.). Also participating were AbbVie Ventures, Alexandria Venture Investments, ARCH Venture, Eli Lilly and Co. (NYSE:LLY), the Johnson & Johnson Innovation - JJDC Inc. unit of Johnson & Johnson (NYSE:JNJ), Watson Fund, WRF Capital and WuXi AppTec Co. Ltd. (Shanghai, China).

Accelerator VP Alice Chen told BioCentury that Rodeo's lead candidate, an inhibitor of hydroxyprostaglandin dehydrogenase 15 NAD (HPGD; 15-PGDH), could be used to treat a broad range of indications in regeneration and repair. Rodeo will focus initially on inflammatory bowel disease (IBD) and blood cell reconstitution following bone marrow transplant...